-
HutchMed’s 2023 Financials Show 102% YOY Revenue Growth and Robust Collaboration with Takeda
•
HutchMed (HKG: 0013, NASDAQ: HCM), a China-based biopharmaceutical company, has released its financial report for 2023, recording a significant increase in revenue to USD 838 million, marking a 102% year-on-year growth calculated on a constant currency basis. The company’s net profits reached USD 101 million, attributed to its collaboration with…
-
Angitia Bio Secures USD 40 Million in Series B+ Financing to Advance Musculoskeletal Disorder Therapies
•
Angitia Biopharmaceuticals, a Guangzhou-based developer of therapies for bone, joint, and muscle diseases, has announced the successful completion of a Series B+ phase II financing round, securing USD 40 million in funds. The round was led by YueKai Health Venture, with the proceeds earmarked to propel the global development of…
-
BMS Taps into Circular RNA Potential with Shanghai Circode Bio Agreement
•
Shanghai Circode Bio has entered into a feasibility study cooperation agreement with US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) to investigate the application feasibility of circular RNA technology within a specific therapeutic area. This collaboration aims to capitalize on Circode Bio’s proprietary circular RNA technology platform and BMS’s extensive…
-
AbbVie Partners with OSE Immunotherapeutics to Develop First-in-Class Immunotherapy OSE-230
•
AbbVie (NYSE: ABBV) has entered into a strategic partnership with France-based OSE Immunotherapeutics (EPA: OSE) to develop the potential first-in-class immunotherapy OSE-230, which is currently in the pre-clinical stage for the treatment of chronic and severe inflammation. Under the terms of the agreement, AbbVie will acquire exclusive global rights to…
-
AstraZeneca’s AZD0486 Receives NMPA Greenlight for Clinical Study in B-Cell Leukemia
•
AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, has received approval from the National Medical Products Administration (NMPA) in China to initiate a clinical study for its drug candidate AZD0486 (TNB-486) in patients with recurrent or refractory B-cell acute lymphoblastic leukemia. AZD0486 is a bispecific antibody (BsAb) that targets both…
-
Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion
•
US generics giant Viatris (NASDAQ: VTRS) reported a 4% year-on-year decline in global sales to USD 15.4 billion in constant currency terms, as detailed in the company’s 2023 financial report. Despite the dip, company president Rajiv Malik declared the completion of the first phase of Viatris’s strategic plan, with the…
-
BMS’s Azacitidine, First Oral AML Therapy, Reaches GBA Patients via Special Policy
•
Bristol-Myers Squibb (BMS, NYSE: BMY), a leading US pharmaceutical company, has announced the clinical application of its drug azacitidine in Shenzhen, within the Guangdong Hong Kong Macao Greater Bay Area (GBA). This marks the use of the world’s first and only oral maintenance therapy for acute myeloid leukemia (AML) in…
-
Abbisko Therapeutics Reports Positive Phase I Results for ABSK061 in Solid Tumors at ESMO TAT 2024
•
Shanghai-based Abbisko Therapeutics Co., Ltd. (HKG: 2256) has revealed promising outcomes from a global, multi-center Phase I trial evaluating the safety, tolerability, pharmacokinetics (PK), and anti-tumor efficacy of its oral FGFR2/3 inhibitor, ABSK061, in treating solid tumors. These findings were presented at the European Society for Medical Oncology (ESMO) TAT…
